- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
The Results and Key Takeaways From GOG0213
Robert L. Coleman, MD, FACOG, FACS
Robert L. Coleman, MD, FACOG, FACS
Robert L. Coleman, MD, FACOG, FACS, professor, The University of Texas MD Anderson Cancer Center, discusses the results and key takeaways from GOG0213.
Robert L. Coleman, MD, FACOG, FACS, professor, The University of Texas MD Anderson Cancer Center, discusses the results and key takeaways from GOG0213. This phase III trial compared carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary, and fallopian tube cancer.
<<<